Jump to content


FYI • Feb. 9 in SF: The 2013 Northern California Emerging Therapies and Survivorship conference

  • Please log in to reply
No replies to this topic

#1 ChrisC


    Advanced Member

  • Members
  • PipPipPip
  • 38 posts

Posted 10 January 2013 - 12:39 PM

I went last year to hear Dr. Shah speak, enjoyed everything about the conference. Have signed up again!

Emerging Therapies and Survivorship for Blood Cancer Patients

An update from the American Society of Hematology (ASH)® Annual Meeting

The Leukemia & Lymphoma Society (LLS) is pleased to bring the latest advances in blood cancer research, clinical trials and disease management to Northern California patients and their caregivers. Please mark your calendars for this special patient conference. Emerging Therapies is a free educational program, but space is limited and registration is required.

Saturday, February 9, 2013
9:00 a.m. - 12:30 p.m.
Hyatt Regency San Francisco (New Location)
5 Embarcadero Center, San Francisco, CA 94111
Emerging Therapies Map

How to register
To reserve your space, please complete the online registration form at:bit.ly/emergingtherapies

Program Agenda
9:00 a.m. Arrival and Breakfast Served

9:30 a.m. LLS Mission Programs Update
Why Public Policy Matters for Blood Cancer Patients

9:45 a.m. Perspectives on Survivorship: A Panel Discussion

10:30 a.m. Concurrent Breakout Sessions
Chronic Lymphoid Leukemia: Steven Coutré, M.D.

Associate Professor of Medicine, Division of Hematology, Stanford University School of Medicine

Chronic Myeloid Leukemia: Neil Shah, M.D., Ph.D.
Assistant Professor, Division of Hematology/Oncology, UCSF School of Medicine

Multiple Myeloma: Jeffrey Wolf, M.D.
Clinical Professor of Medicine and Director of the Myeloma Institute, Helen Diller Family Comprehensive Cancer Center, UCSF

Myelodysplastic Syndromes: Peter Greenberg, M.D.
Professor Emeritus, Medicine - Hematology, Stanford University School of Medicine

Non-Hodgkin Lymphoma (High Grade/Aggressive): Weiyun Ai, M.D., Ph.D.
Clinical Assistant Professor of Medicine; Division of Hematology/Oncology, UCSF

Non-Hodgkin Lymphoma (Low Grade/Indolent): C. Babis Andreadis, M.D., MSCE
Assistant Clinical Professor of Medicine, Adult Bone Marrow Transplantation Program, Helen Diller Family Comprehensive Cancer Center, UCSF

The 2013 Northern California Emerging Therapies and Survivorship conference is made possible by the generosity of our partners and sponsors.

2013 Partners: Association of Northern California Oncologists, Marin Specialty Care, Redwood Regional Oncology Center, Stanford Cancer Center, and University of California, San Francisco Helen Diller Family Comprehensive Cancer Center

2013 Sponsors: Millennium, Genentech, Onyx Pharmaceuticals, Celgene and Teva

Be alert, but not overly concerned.


• Dx Oct. 22, 2008, WBC 459k, in ICU for 2 days + in hospital 1 week

• Leukapheresis for 1 week, to reduce WBC (wasn't given Hydroxyurea)

• Oct. 28, 2008: CML confirmed, start Gleevec 400mg

• Oct. 31, 2008: sent home when WBC reached 121k

• On/off, reduced dose Gleevec for 7 months

• April 2009: Started Sprycel 100mg

• Sept. 2009: PCRU 0.000

• Sept. 2011: after 2 years steady PCRU & taking Sprycel 100mg before bed, quit Sprycel (with permission)

• Currently: still steady PCRU, testing every 6 months 🤗

— Fatigue, hearing loss continue, alas, but I prefer to think it is all getting better!



1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users